Inhibition of BRD4 triggers cellular senescence through suppressing aurora kinases in oesophageal cancer cells

Interference with the bromodomain epigenome readers drives p21 expression and tumor senescence

(2019) Liana P. Webber et al.   CANCER LETTERS

BRD4 regulates cellular senescence in gastric cancer cells via E2F/miR-106b/p21 axis

(2018) Xingchen Dong et al.   Cell Death & Disease

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses

(2017) Zefang Tang et al.   NUCLEIC ACIDS RESEARCH

Bromodomain protein 4 is a novel predictor of survival for gastric carcinoma

(2017) Yixin Zhu et al.   Oncotarget

Cancer statistics in China, 2015

(2016) Wanqing Chen et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases

(2016) Jennifer M. Sahni et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

BET inhibition as a new strategy for the treatment of gastric cancer

(2016) Raquel C. Montenegro et al.   Oncotarget

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Update on Metastatic Gastric and Esophageal Cancers

(2015) Manish A. Shah   JOURNAL OF CLINICAL ONCOLOGY

Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery

(2015) Lei-lei Fu et al.   Oncotarget

Loss of miR-200b promotes invasion via activating the Kindlin-2/integrin β1/AKT pathway in esophageal squamous cell carcinoma: An E-cadherin-independent mechanism

(2015) Hai-Feng Zhang et al.   Oncotarget

BET bromodomain proteins are required for glioblastoma cell proliferation

(2014) Chiara Pastori et al.   Epigenetics

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

(2014) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition

(2014) Junwei Shi et al.   MOLECULAR CELL

PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies

(2014) Thomas De Raedt et al.   NATURE

Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151

(2014) Stuart J. Gallagher et al.   Pigment Cell & Melanoma Research

Bromodomain and Extraterminal Domain Inhibitors (BETi) for Cancer Therapy: Chemical Modulation of Chromatin Structure

(2014) J. Qi   Cold Spring Harbor Perspectives in Biology

Two nonsynonymous polymorphisms (F31I and V57I) of the STK15 gene and breast cancer risk: A meta-analysis based on 5966 cases and 7609 controls

(2013) Kai Qin et al.   JOURNAL OF INTERNATIONAL MEDICAL RESEARCH

Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors

(2013) B Tolani et al.   ONCOGENE

BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia

(2012) C. J. Ott et al.   BLOOD

Association of Aurora-A (STK15) kinase polymorphisms with clinical outcome of esophageal cancer treated with preoperative chemoradiation

(2011) Jennifer Y. Pan et al.   CANCER

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

(2011) Jake E. Delmore et al.   CELL

Targeting MYC dependence in cancer by inhibiting BET bromodomains

(2011) J. A. Mertz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Selective inhibition of BET bromodomains

(2010) Panagis Filippakopoulos et al.   NATURE

Esophageal cancer: An update

(2010) C.M. Shahbaz Sarwar et al.   International Journal of Surgery

The Changing Face of Esophageal Cancer

(2010) Rachel E. Melhado et al.   Cancers